Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
Abstract A deep understanding of the biological mechanisms driving the pathogenesis of myelodysplastic neoplasms (MDS) is essential to develop comprehensive therapeutic approaches that will benefit patient's disease management and quality of life. In this review, we focus on MDS harboring mutat...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | HemaSphere |
| Online Access: | https://doi.org/10.1002/hem3.70103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|